DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Paul Edison - 4 Edison - 4 Dr - 4 liraglutide - 2 Stephen Evans - 2 Jason Kirk - 2 Quynh Nguyen - 2 hadn't - 2
Top related locs:
Philadelphia Novo Danish United Kingdom Alzheimer’s ” Novo Provo , Utah Biogen
Top related orgs:
Novo Nordisk - 4 Imperial College London - 4 Alzheimer's Association International Conference - 3 Service - 2 London School of Hygiene - 2 Medicine - 2 Science Media - 2 Nikon - 2

Search resuls for: "Paul Edison"


4 mentions found


☆ Ozempic predecessor suggests potential for GLP-1 drugs in Alzheimer’s in early trial
  + stars: | 2024-07-30 | by ( Meg Tirrell | ) edition.cnn.com   time to read: +7 min
“This is the first study that actually looked at a relatively large number of patients for whether there is any neuroprotective effect in Alzheimer’s disease,” Edison said. The trial enrolled predominantly people with mild Alzheimer’s disease, measured by a test known as the Mini-Mental State Examination, a scale that goes up to 30. The GLP-1 drug class also includes Eli Lilly’s Mounjaro and Zepbound, which use the active ingredient tirzepatide, which mimics not just the hormone GLP-1 but another called GIP. But it hasn’t announced any trials of its GLP-1 drugs in Alzheimer’s. GLP-1 drugs can have side effects, though, primarily gastrointestinal problems like nausea and vomiting.
Persons: liraglutide, “, ”, Maria Carrillo, Carrillo, Paul Edison, ” Edison, Edison, Eli Lilly’s Mounjaro, Alzheimer’s Lilly, hasn’t, Lilly, Lars Fruergaard Jorgensen, there’s, Dr, Sanjay Gupta, semaglutide Organizations: CNN, Alzheimer’s Association International Conference, Alzheimer’s Association, Novo Nordisk, Imperial College London, ”, Nordisk, ” Novo Nordisk, CNN Health, University of Oxford, Alzheimer’s Society, Alzheimer’s Locations: United Kingdom, Philadelphia, Alzheimer’s, ” Novo, Danish
☆ Weight-loss drugs could stave off dementia, small study finds
  + stars: | 2024-07-30 | by ( Hilary Brueck | ) www.businessinsider.com   time to read: +6 min
Today, a group of dementia researchers from the UK released some early results that suggest it's possible these trendy injections might also stall the progression of dementia. A daily injection for brain preservationIuliia Burmistrova/Getty ImagesFor the study, researchers spent a year tracking brain changes across 204 Alzheimer's patients with mild to moderate disease. "It sounds like it is worth pursuing a larger trial, but these results cannot demonstrate that liraglutide can protect against dementia." Experts have seen how dementia patients' brains get worse and worse at efficiently using glucose for energy as their disease progresses, but the calculus is always complicated. Bigger studies using more powerful GLP-1 drugs for dementia are already ongoing.
Persons: Stephen Evans, Jason Kirk, Quynh Nguyen, hadn't, Dr, Paul Edison, it's, Edison, Alzheimer's Organizations: Service, Alzheimer's Association International Conference, London School of Hygiene, Medicine, Science Media, Nikon, Imperial College London, Food and Drug Administration, Novo Nordisk Locations: Philadelphia, Novo
☆ Scientists say weight-loss drugs could protect our brains from dementia. Early results suggest they're onto something.
  + stars: | 2024-07-30 | by ( Hilary Brueck | ) www.businessinsider.com   time to read: +6 min
Today, a group of dementia researchers from the UK released some early results that suggest it's possible these trendy injections might also stall the progression of dementia. A daily injection for brain preservationIuliia Burmistrova/Getty ImagesFor the study, researchers spent a year tracking brain changes across 204 Alzheimer's patients with mild to moderate disease. "It sounds like it is worth pursuing a larger trial, but these results cannot demonstrate that liraglutide can protect against dementia." Experts have seen how dementia patients' brains get worse and worse at efficiently using glucose for energy as their disease progresses, but the calculus is always complicated. Bigger studies using more powerful GLP-1 drugs for dementia are already ongoing.
Persons: Stephen Evans, Jason Kirk, Quynh Nguyen, hadn't, Dr, Paul Edison, it's, Edison, Alzheimer's Organizations: Service, Alzheimer's Association International Conference, London School of Hygiene, Medicine, Science Media, Nikon, Imperial College London, Food and Drug Administration, Novo Nordisk Locations: Philadelphia, Novo
☆ Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
  + stars: | 2024-07-30 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +5 min
George Frey | ReutersAn older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer's disease by protecting patients' brains, according to data from a mid-stage trial released on Tuesday. Novo Nordisk sells liraglutide as a diabetes and obesity drug under the brand names Victoza and Saxenda, respectively. Alzheimer's disease often causes the brain to shrink as the illness progresses because crucial nerve cells break down and stop working properly. By 2050, the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S. The ongoing EVOKE is examining semaglutide, the active ingredient in Wegovy and Ozempic, in nearly 2,000 Alzheimer's patients.
Persons: George Frey, Eli Lilly, liraglutide, Brian B, Bettencourt, Heather Snyder, Leqembi, Snyder, Dr, Paul Edison, Edison, Bobby Pugh, Bessie Pugh, Karen Pulfer Focht Organizations: Novo Nordisk Pharmaceutical, Reuters, Novo Nordisk, Imperial College London, Alzheimer's Association International Conference, Toronto Star, Getty, Alzheimer's Association, U.S, CNBC, Alzheimer's, Novo Nordisk's, Ave Locations: Provo , Utah, Danish, Philadelphia, Biogen, Novo, Bartlett , Tennessee, U.S
0 next >>
Total: 4